Completed

The Effects of Sildenafil on Exercise Function and Capacity in Patients With Fontan Circulation

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Sildenafil

+ Placebo 2

+ Placebo

Drug
Who is being recruted

From 6 to 17 Years
+10 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Placebo-ControlledPhase 4
Interventional
Study Start: August 2009
See protocol details

Summary

Principal SponsorMilton S. Hershey Medical Center
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: August 1, 2009

Actual date on which the first participant was enrolled.

The study will test the hypothesis that a single dose of sildenafil can increase the exercise capacity of pediatric patients with a Fontan Circulation.

Official TitleThe Effects of Sildenafil on Exercise Function and Capacity in Patients With Fontan Circulation
Principal SponsorMilton S. Hershey Medical Center
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

17 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 6 to 17 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Criteria

3 inclusion criteria required to participate
Age 6-17 years

Male or female

Possess Fontan Circulation

7 exclusion criteria prevent from participating
Severe heart failure (New York Heart Ass. functional class IV)

Evidence of Fontan pathway obstruction

History of exercise-induced severe arrhythmias

Pregnancy (known or suspected)

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

50% chance of being blinded to the placebo group

Treatment Groups

Group I

Active Comparator
Sildenafil dosage (0.5mg/kg (max 20mg)) administered at the time of enrollment followed by a battery of exercise tests. After a washout period, the process will be repeated with treatment 2, placebo drug administered before the exercises.

Group II

Placebo
Patient will receive a look-alike placebo administered at the time of enrollment followed by a battery of exercise tests. After a washout period, the process will be repeated with treatment 2 Sildenafil dosage will be 0.5mg/kg (max 20mg) administered before the exercises.

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Penn State Hershey Medical Center

Hershey, United StatesOpen Penn State Hershey Medical Center in Google Maps
CompletedOne Study Center